Clinical and diagnostic characteristics of hyperprolactinemia in childhood and adolescence

Journal of Pediatric Endocrinology and Metabolism

Volumn 26, Issue 1-2, 2013, Pages 1-11

  Catli, Gonul ^b   Abaci, Ayhan ^b   Bober, Ece ^b   Büÿgebiz, Atilla ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Childhood; Macroprolactin; Prolactinoma

Indexed keywords

4 AMINOBUTYRIC ACID; BROMOCRIPTINE; CABERGOLINE; FOLLITROPIN; GLIBENCLAMIDE; LISURIDE; LUTEINIZING HORMONE; METOCLOPRAMIDE; PERGOLIDE; PHENOTHIAZINE; PROLACTIN; QUINAGOLIDE; RISPERIDONE; SOMATOSTATIN;

ABDOMINAL PAIN; ADENOMA; ADOLESCENT DISEASE; BRAIN TUMOR; CAVERNOUS SINUS; CEREBROVASCULAR ACCIDENT; CHILD CARE; CHILDHOOD DISEASE; CHILDHOOD OBESITY; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CRANIOPHARYNGIOMA; DELAYED PUBERTY; DIABETES INSIPIDUS; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DOPAMINE RELEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FATIGUE; FOLLITROPIN BLOOD LEVEL; GALACTORRHEA; GAMMA KNIFE RADIOSURGERY; GROWTH RETARDATION; GYNECOMASTIA; HEADACHE; HEART MUSCLE FIBROSIS; HEMIANOPIA; HORMONAL REGULATION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHYROIDISM; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LIQUORRHEA; LIVER FUNCTION TEST; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MENINGITIS; MENSTRUATION DISORDER; MICROADENOMA; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; ORTHOSTATIC HYPOTENSION; OSTEOPENIA; OSTEOPOROSIS; OVARY CYST; PARESTHESIA; PHYSICAL EXAMINATION; PITUITARY STALK; PRECOCIOUS PUBERTY; PREGNANCY TEST; PRIMARY AMENORRHEA; PROLACTIN BLOOD LEVEL; PROLACTIN SYNTHESIS; PROLACTINOMA; RECOMMENDED DRUG DOSE; RETROPERITONEAL FIBROSIS; REVIEW; RHINORRHEA; SECONDARY AMENORRHEA; SEX DIFFERENCE; SEXUAL FUNCTION; SHORT STATURE; THYROID FUNCTION TEST; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; VALVULAR HEART DISEASE; VISUAL DISORDER; VISUAL FIELD; VISUAL FIELD DEFECT; VOMITING;

ADOLESCENT; AGE OF ONSET; ALGORITHMS; CHILD; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE;

EID: 84878292253     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2012-0327     Document Type: Review

References (70)

1. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273 - 88.
2. Patel SS, Bamigboye V. Hyperprolactinaemia. J Obstet Gynaecol 2007;27:455 - 9. (Pubitemid 47295303)
3. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008;37:67 - 99. (Pubitemid 351146629)
4. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265 - 73. (Pubitemid 44079693)
5. Colao A, Loche S, Cappa M, Di SA, Landi ML, et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777 - 80. (Pubitemid 28493775)
6. Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 1981;3:163 - 83. (Pubitemid 12164158)
7. Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, et al. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr 2010;73:187 - 92.
8. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, et al. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 2006;104:54 - 61.
9. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22:109 - 14. (Pubitemid 34289384)
10. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocr Pract 2000;6:425 - 9.
11. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am 2001;30:585 - 610. (Pubitemid 32852805)
12. Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125:152 - 64.
13. Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, et al. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocr Met 2000;13:261 - 7. (Pubitemid 30163750)
14. Fideleff HL, Boquete HR, Suarez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res 2009;72:197 - 205.
15. Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, et al. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol (Oxf) 1989;30:131- 40. (Pubitemid 19063217)
16. Colao A, Di SC, Loche S, Di SA, Klain M, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000;52:319 - 27. (Pubitemid 30169688)
17. Catli G, Abaci A, Altincik A, Demir K, Can S, et al. Hyperprolactinemia in children: Clinical features and long-term results. J Pediatr Endocr Met 2012;25:1123-8.
18. Eren E, Yapici S, Cakir ED, Ceylan LA, Saglam H, et al. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011;3:65 - 9.
19. Hekimsoy Z, Kafesciler S, Guclu F, Ozmen B. The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J 2010;57:1011- 5.
20. Glezer A, Bronstein MD. Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J Clin Endocrinol Metab 2012;97:2211- 6.
21. Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 2008;31:436 - 44. (Pubitemid 352005743)
22. Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, et al. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 2006;91:1048- 55. (Pubitemid 43357779)
23. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985;6:245 - 9. (Pubitemid 16257626)
24. Muneyyirci-Delale O, Goldstein D, Reyes FI. Diagnosis of stress-related hyperprolactinemia. Evaluation of the hyperprolactinemia rest test. NY State J Med 1989;89:205 - 8.
25. Filho RB, Domingues L, Naves L, Ferraz E, Alves A, et al. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007;23:267 - 72. (Pubitemid 46897698)
26. Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003;92:171 - 7. (Pubitemid 36992303)
27. McKenna TJ. Should macroprolactin be measured in all hyperprolactinaemic sera ? Clin Endocrinol (Oxf) 2009;71:466 - 9.
28. Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf) 2009;70:599 - 605.
29. De BA, Colao A, Pivonello R, Savoia A, Battaglia M, et al. Antipituitary antibodies in idiopathic hyperprolactinemic patients. Ann NY Acad Sci 2007;1107:129 - 35. (Pubitemid 47528789)
30. Hauache OM, Rocha AJ, Maia AC Jr., Maciel RM, Vieira JG. Screening for macroprolactinaemia and pituitary imaging studies. Clin Endocrinol (Oxf) 2002;57:327 - 31. (Pubitemid 35013811)
31. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581 - 8. (Pubitemid 34158222)
32. Tutunculer F, Darendeliler F, Aygun M, Hekim N. Macroprolactinemia in childhood and adolescence: a cause of hyperprolactinemia. Turk J Pediatr 2006;48:143 - 7. (Pubitemid 44070366)
33. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005;90:3927 - 32. (Pubitemid 41058153)
34. Mounier C, Trouillas J, Claustrat B, Duthel R, Estour B. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003;18:853 - 7. (Pubitemid 36426970)
35. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87:5410- 5. (Pubitemid 36034335)
36. Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008;11:141 - 6.
37. Comtois R, Robert F, Hardy J. Immunoradiometric assays may miss high prolactin levels. Ann Intern Med 1993;119:173.
38. Stites DP, Channing Rodgers RP, Folds JD, et al. Clinical laboratory methods for detection of antigens and antibodies. In: Stites DP, Terr AI, Parslow TG, editors, Medical immunology 9th ed, Connecticut: Appleton and Lange, 1997:211 - 53.
39. Wolf BA, Garrett NC, Nahm MH. The " hook effect": high concentrations of prostate-specific antigen giving artifactually low values on one-step immunoassay. N Engl J Med 1989;320:1755 - 6. (Pubitemid 19163139)
40. Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the " high-dose hook effect " : case report. Neurosurgery 1998;42:913 - 5.
41. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305 - 9.
42. Ahmadi J, North CM, Segall HD, Zee CS, Weiss MH. Cavernous sinus invasion by pituitary adenomas. AJR Am J Roentgenol 1986;146:257 - 62. (Pubitemid 16143913)
43. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009;160:747 - 52.
44. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of trans-sphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997;40:225 - 36.
45. Ma W, Ikeda H, Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 2002;95:258 - 66. (Pubitemid 34787590)
46. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412 - 8. (Pubitemid 19052886)
47. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 2005;63:26 - 31. (Pubitemid 40966398)
48. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485 - 534. (Pubitemid 44213229)
49. Sakazume S, Obata K, Takahashi E, Yoshino A, Murakami N, et al. Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child. Eur J Pediatr 2004;163:472 - 4. (Pubitemid 39013121)
50. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904 - 9. (Pubitemid 24299871)
51. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003;2:23- 32. (Pubitemid 37051600)
52. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008;159:1 - 5. (Pubitemid 351969123)
53. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976 - 7. (Pubitemid 41565968)
54. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6 - 9.
55. Harrington MH, Casella SJ. Pituitary tumors in childhood. Curr Opin Endocrinol Diabetes Obes 2012;19:63 - 7.
56. Gillam MP, Fideleff H, Boquete HR, Molitch ME. Prolactin excess: treatment and toxicity. Pediatr Endocrinol Rev 2004;2(Suppl 1): 108 - 14. (Pubitemid 40129189)
57. Miller KK. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectr 2004;9(8 Suppl 7): 28 - 32. (Pubitemid 39180995)
58. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;65:187 - 90.
59. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001;11:435 - 40. (Pubitemid 34117293)
60. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000;23:765 - 70. (Pubitemid 32041058)
61. Pereira AM. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Curr Opin Endocrinol Diabetes Obes 2011;18:264- 8.
62. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued ? J Clin Endocrinol Metab 2009;94:2247 - 9.
63. Faglia G. Should dopamine agonist treatment for prolactinomas be life-long? Clin Endocrinol (Oxf) 1991;34:173 - 4.
64. Colao A, Di SA, Cappabianca P, Di SC, Pivonello R, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349: 2023 - 33. (Pubitemid 37448925)
65. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009;94:2428 - 36.
66. Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, et al. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg 1995;82:886 - 90.
67. Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006;2:552 - 61. (Pubitemid 44536603)
68. Liu X, Kano H, Kondziolka D, Park KJ, Iyer A, et al. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary 2012 doi 10.1007/s11102-012-0376-x.
69. Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF Jr. et al. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 2010;74:147 - 52.
70. Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg 2000;93(Suppl 3):14- 8. (Pubitemid 32799538)